HTA17 Comparison of Methods for Modelling the Cost-Effectiveness of Atezolizumab as an Adjuvant Treatment in Stage II-IIIA Non-Small Cell Lung Cancer

Abstract

Authors

N. Jovanoski C.Y. Yip

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×